Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The sequential method of contraception with megestrol acetate with ethinyl estradiol was offered to 61 women for 549 cycles in this study. No pregnancies occurred. Flow was less in 7 women and greater in 3; duration of flow was longer in 5 women and shorter in 3. There were 2 instances of breakthrough bleeding. Persistant postnatal amenorrhea occurred in 1 woman and menorrhagia in another. Random endometrial biopsies showed proliferative activity in the majority of cases. Side effects observed were: nausea, vomiting, giddiness, leucorrhea, headache, weakness and abdominal pain. Most of these symptoms occurred in the first 2 cycles. 29 women dropped out after the first year, and 8 of these women conceived. Ethinyl estradiol was used in .1mg dose, megestrol acetate in 1 mg.
 ...
PMID:Evaluation of sequential method of contraception with megestrol acetate and ethinyl oestradiol. 1215 52

The Norplant system is a long-acting hormonal contraceptive method for women which offers high efficacy. The active principal is levonorgestrel, a progestin widely used in oral contraceptives. The Norplant system is in use in various countries including the US, the Dominican Republic, Colombia, Brazil, Chile, Sweden, and Denmark. Norplant consists of silastic capsules containing levonorgestrel which are inserted subdermally in the arm. The progestin is released in constant form from the moment of implantation. 50 mcg are released daily during the first year and approximately 30 mcg are released in subsequent years. Norplant is effective for at least 5 years if a set of 6 capsules is used. Norplant II, consisting of 2 capsules used for 3 years, has come into use more recently. The cumulative pregnancy rate after 5 years of use by 992 women was 2.7/100 continuous users. The annual pregnancy rate was generally less than .5%. No other reversible method has demonstrated the same level of effectiveness during such prolonged periods of use. The mechanism of action is based on inhibition of ovulation in about 50% of cycles, thickening of cervical mucus, and endometrial suppression. Norplant users may present some adverse effects such as menstrual irregularities, amenorrhea, nausea, dizziness, or headaches, but these symptoms are less frequent than with other hormonal methods. Menstrual irregularity is the most frequent secondary effect and the principal cause of termination of use. The secondary effects are generally acceptable. Follow-up during the period of effectiveness of the implants is simple and infrequent. Norplant is an excellent contraceptive choice for women who do not desire pregnancy but do not wish to use a definitive contraceptive method. Once the implant is removed, fertility rapidly is restored.
 ...
PMID:[Norplant: a new alternative in family planning]. 1217 15

The acceptability of 2 and 3 month injectable contraceptives was assessed and compared, and the acceptability of the injectables was further compared with that of oral contraceptives (OCs) and IUDs among a random sample of women, who attended a clinic in Alexandria, Egypt. The study was conducted by the University of Alexandria. The sample included 100 acceptors of the 2-month injectable, norethisterone oenanthate (NET-O EN), 100 acceptors of the 3-month injectable, depo-medroxy pregesterone acetate (DPMA), 60 OC acceptors, and 60 IUD acceptors. The women were interviewed prior to treatment and 2 or 3 times during the 6 months following their initial acceptance of the methods. Women who discontinued at any time during the 6-month period were interviewed concerning their reasons for discontinuing. The data was analyzed by calculating means and % distribution and by testing for significance. The percent lost to follow up was 12% for the NET-O EN group, 12% for DPMA users, and 0% for IUD and OC acceptors. The mean age of the acceptors was 30.4 years for NET-O EN, 30.7 years for DMPA, 28.3 years for OCs, and 25.2 years for IUDs. For these acceptor groups, the respective mean number of years of schooling was 6.1, 5.2, 7.2, and 7.5, and the respective mean number of pregnancies was 5.6, 5.4, 3.8, and 2.9. All 320 of the women were married, and 319 were Muslim. 99.4% lived in urban areas. 10% had no living male children, and 23.7% had no living female children. 2/3 of the injectable acceptors previously used 2 or more fertility control methods. A higher percent of IUD and OC acceptors, compared to injectable acceptors, reported using only 1 or no previous method. More than 1/2 of the injectable acceptors reported disruptions in their normal bleeding patterns. NET-O EN acceptors were more likely to experience heavy or prolonged bleeding while DPMA acceptors were more likely to report amenorrhea or a decreased flow. IUD acceptors were also bothered by bleeding problems. Almost all the women who reported changes in bleeding patterns were unhappy about the changes. Many of the women who reported amenorrhea worried that they might be pregnant. Women who experienced heavy or unpredictable bleeding worried about anemia and complained that bleeding interfered with their daily routines. 47.6% of the women reported weight gains, but this was generally viewed as an advantage. Nausea was the major side effect associated with OC use. 32% of the OC users, 28.0% of the NET-E ON users, 30.0% of the DMPA users, and none of the IUD users reported nausea. For all 4 groups, convenience and effectiveness were the major advantages the women attributed to their chosen method. Continuation rates were 68% for NET-O EN, 70% for DMPA, 75% for OCs, and 75% for IUDs. The major reason for discontinuation of injectables was bleeding problems. Among injectable users, a higher proportion of discontinuers (49%) than of continuers (20%) reported amenorrhea. The findings suggest that continuation for injectables could be improved if patients were given more detailed information about possible side effects and if they were advised to return to the clinic for treatment of any symptoms they experience.
 ...
PMID:Acceptability study of the two versus three monthly injectable contraceptives. 1217 96

An experimental drug - bromocriptine - apparently restores menses and suppresses prolactin production in women with amenorrhea and galactorrhea. Side effects such as nausea, vomiting, lightheadedness, and mild ankle edema usually abate after the first few weeks of therapy. In a study of 13 women with elevated prolactin levels who were treated with 2.5 mg of bromocriptone orally twice a day for up to 24 weeks, galactorrhea diminished markedly in all the patients. Only 5 had complete cessation of galactorrhea. Galactorrhea returned in 11 patients when they stopped taking the drug. Menses were restored in 10 of the women after 3-10 1/2 weeks of treatment. 3 women became pregnant before the resumption of menses. The degree of prolactin suppression (reduced to less than 20 ng/ml in a patient) failed to correlate well with early or late resumption of menses or conception.
 ...
PMID:New drug helps women with "post-pill" problem. 1222 78

The benefits of using oral contraceptives with low estrogen content (50 mcg or less) or minipills are discussed. Although no incontrovertible statistical evidence is available, a study by the Royal College of General Practitioners in Great Britain showed that the incidence of thrombosis was decreased by 25% with the use of low estrogen oral contraceptives. Low estrogen oral contraceptives can have relatively estrogenic or progestational effects, depending on the type and ratio of estrogen/progestin components used. Clinical observation of the individual patient using oral contraceptives is important. Patients suffering from estrogen-related side effects (e.g., nausea, fluid retention) can be switched to relatively progestational low-estrogen oral contraceptives, and vice versa. Minipills are not as widely publicized because of a failure rate of 1-4 pregnancies/100 woman-years, a patient dropout rate of up to 50%, and progestin side effects (e.g., amenorrhea, breakthrough bleeding). Ectopic pregnancy seems to be more frequent with minipill use. Minipills are used for estrogen-sensitive women, women with thromboembolic disease, and breast-feeding women. The minipill is less likely to endanger the life of the mother or fetus in the case of pregnancy than is IUD use.
 ...
PMID:The pill: is low estrogen the answer? 1222 73

185 women received chlormadinone acetate (a 19-hydroxyprogesterone derivative) .5 mg daily, for 18 months. All (aged 20-40 years) were parous. 180 women were followed through 2280 cycles. Dropout rate was highest in the first cycle (44%), 4% from the sixth to the twelfth cycles, and about 1% after the thirteenth cycle. Side effects were 2%: breakthrough bleeding, amenorrhea, menorrhea, dysmenorrhea, abdominal pain pregnancy, nausea, weakness forgetfulness, giddiness and headache, burning sensation, red spots on skin, and thrombophlebitis. Breakthrough bleeding (14 cases), amenorrhea (12 cases) and weakness (8 cases) were the most frequently reported problems. Phlebitis was seen in 1 case. 40 of the 48 cases of side effects were seen before the sixth cycle. There were 3 pregnancies during the study: 1 woman was pregnant at the beginning of therapy and 2 were due to patient failure. A review of the literature followed, including a discussion on the mode of action of chlormadinone.
 ...
PMID:Chlormadinone acetate as an oral contraceptive. 1225 95

A clinical study of a daily dosage of .5 chlormadinone acetate, a progestagen, was carried out on 101 randomly chosen women for a total of 954 cycles in Galaa Hospital and in the University Hospital Mansoura Faculty of Medicine. There were no reportedly pregnancies. One patient discontinued use after 16 days because of continuous bleeding. There were 20 dropouts between cycles 1-8 with reasons not investigated. Minor side effects included headache, giddiness, nausea, distension and breast discomfort. Of 34 lactating women in the study, 32 reported no effect on lactation and 2 reported diminished lactation. Amenorrhea was reported in 10% of the cycles. Cervicle mucus studies showed the mucus to be hostile to sperm.
 ...
PMID:Low dosage gestagens in fertility control. 1225 12

Dr. J.M. Manautou, Director of Research, Mexican Institute of Social Security, gave a report on a study of continuous administration of 500 mug. of chlormadinone acetate to regulate fertility without inhibiting ovulation. Smaller doses (400,300 and 250 mug.) were used as well, in fewer patients and with less satisfactory results. The 500 mug. dose was used in 1123 women for a total of 13,202 cycles; 121 of these women received the treatment for 21 uninterrupted cycles. All the women in this study were under 36 years of age. Of the 1123 women on the 500 mug. dose, 40 became pregnant; six of these pregnancies were taken to be method failures because the women denied suspending treatment at any stage, and the other 34 were classed as patient failures. This gave a clinical efficiency for the method of 3.7 pregnancies per 100 woman-years. A special test was carried out on some of the women taking part in the study to check their accuracy regarding omission of treatment. Nearly half of those tested left out one or more tablets without admitting this; the presentation of the tablets did not allow the women to check whether they had omitted tablets or not. Dr. Manautou considered that better presentation would keep the women informed about the number of tablets they had taken and would obviate patient failures. Chlormadinone acetate was taken by 10 women who had become pregnant, until their amenorrhoea was correctly diagnosed. All these pregnancies were normal, with eight male and two female babies. No congenital abnormalities or signs of virilization were found. On continuous administration of chlormadinone acetate, menstrual bleeding occurred at 21-24 day intervals in 11.8% of cycles, at 25-35 day intervals in 65.5% of cycles, and at 36-59 day intervals in 20.6%. In no case did menstruation cease. In only 19 women was there menorrhagia of such proportions that the tablets had to be stopped. Intermenstrual bleeding occurred in 20.3% during the first cycle of administration; this percentage decreased over successive cycles until by the 20st cycle it occurred in only 2.1%. In most cases it was slight. Mechanism of action: This is not yet completely clear, but a number of investigations were carried out to try to discover how the compound acts. In 380 endometrial biopsies, 37.9% were irregularly secretory, 30.5% normally secretory, 15% irregular, 9.5% proliferative, and only 7.1% inactive. Culdoscopic studies were carried out in 50 women; in 37 a corpus luteum was present, in six the ovary appeared inactive, in three there was follicular activity without corpus luteum formation, three had cysts in the ovary, and one had a -corpus luteum not of recent origin. In 18 of the 37 cases in which a corpus luteum was found ovarian biopsy was done. The presence of an active corpus luteum was diagnosed in 12. Cervical mucus was investigated in 115 women between the 12th and 16th days of the first three cycles of continuous treatment. The physico-chemical characteristics of the mucus were modified in a way that made it hostile to the entry of sperms. Further, more precise, tests on the cervical mucus will need to be done to reach definite conclusions in this respect. There was a low incidence of side-effects caused by hormonal imbalance, such as nausea, vomiting, chloasma, and mastalgia. The only side-effect that was troublesome was breakthrough bleeding.
 ...
PMID:Low-dose oral products. 1225 2

Long-acting injectable progestagens have been studied in field trials in Thailand, Chile, and the U.S., using doses varying from 150 mg to 300 mg. Problems associated with this treatment are irregular bleeding, amenorrhea, and inhibition of ovulation after the treatment has been discontinued. Low-dose continuous oral progestagens also create an unpredictable bleeding pattern. Serious adverse effects such as thromboembolism, liver dysfunction, and nausea are reduced. In Mexico the once-a-month pill proved successful in preventing pregnancy and was considered useful for uneducated women because of its simplicity. Problems following IUD insertion may include acute salpingitis, pelvic abscess, septic shock, and subphrenic abscess. Prepackaged inserters and devices along with strict aseptis during insertion will help to reduce septic complications. Data from Japan shows that long term use of IUDs is not associated with troublesome side effects.
 ...
PMID:Sixth fertility and sterility congress--a review. 1225 97

The Indian Contraceptive Testing Unit started making field trials with oral contraceptives in 1964. By June 1968, 958 women were taking oral contraceptives. Combination tablets used contained a minimum amount of progestogen (.5-3 mg) and a suitable amount of estrogen. The 21-tablet pack was found mot suitable. It was found that if a woman missed taking the tablets in the latter half of the cycle usually no harm resulted, but if she missed them at the beginning of the cycle pregnancy might follow as ovulation would not be inhibited. Main contraindications are liver damage, toxic hyperthyroidism, thromboembolic disease, and cancer of the genital tract or breast. Caution is advised for persons with chronic nephritis, a history of eclampsia, hypertension, varicose veins, ophthalmological disorders, or psychic depressive states. Side effects have been less with the smaller doses. The most serious side effect is thromboembolism. Those reported have been leg pain, giddiness, headache, breakthrough bleeding, nausea, vomiting, amenorrhea, abdominal pain, weakness, increased blood pressure, and skin rashes. Others have reported ocular disease and cranial nerve palsy. Sequential therapy has been reported to have a lower incidence of side effects but a higher rate of pregnancy. Low-dose progestogen therapy, the "minipill," does not inhibit ovulation but is effective by causing changes in the endometrium and in the mucus. The chlormadinone in the minipill does not affect lactation. However, the incidence of pregnancy is similar to that with an IUD (Lippes loop) which is 2.6/100 cases. Laboratory tests have been normal, except an increase in the thymol turbidity test. Vaginal cytology has revealed no case of malignancy. Results show that oral contraceptives are suitable for use on a mass scale as a method of population control.
 ...
PMID:Experience with oral contraceptives. 1225 72


<< Previous 1 2 3 4 5 6 7 8 9 10